Great uncertainty in Medicaid enrollment and costs from reforms
NICE guidelines for treating hyperglycaemia in ACS...
WHO issues new rubella vaccination recommendations
Essential chemo drugs in short supply in the USA
Is England's new health regulator, Monitor, set to fail?
Use of copay coupons for branded drugs will raise healthcare costs
Most RA care inconsistent with current ACR guidelines
The Medical Technologies Evaluation Programme at NICE has commissioned a new external assessment centre
Updated guidelines for the management of community acquired pneumonia in children have been published by the British Thoracic Society.
News from EMCC
An antibacterial stewardship programme using a computerised surveillance system saves costs,
Brain disorders "number one economic challenge" for Europe
PCV-13 vaccination proves its worth in a US pandemic ...
Dabigatran etexilate: a winner vs warfarin in the UK context
What are the real costs of severe sepsis in the USA?
UK efficient at reducing cancer mortality
Bearing the burden of fertility treatment choices
Financial impact of a measles outbreak substantial
Un-willingness to pay for adverse drug event regulatory actions
Adding memantine saves costs for Alzheimer's disease in Canada
Linezolid reduces re-hospitalisation and lowers costs
Hospitalisation drives high costs of COPD in Singapore
Costs and use of oral cancer drugs on the rise
Atorvastatin proves its worth over the long-term
Endostatin unlikely to be a cost-effective addition for NSCLC
Interferon-β-1b: cost effective for early-phase MS in the US
Mass vaccination for seasonal influenza saves costs in the USA
Benlysta will drive the SLE market
NICE news for mifamurtide, tocilizumab and ticagrelor
Latest advice from the SMC
AstraZeneca have announced the launch of a new Crestor [rosuvastatin] savings card for both insured and uninsured patients.
Canada's NACI* says the needle-free, nasal spray FluMist is the preferred influenza vaccine for children aged 2−17 years
A CDC* panel has recommended the human papillomavirus (HPV) vaccine for boys aged 11-12 years,
Pharmaceutical companies continue to pay potential generic rivals to delay the introduction of their lower-cost drugs,
US pharmacists are campaigning against high prescription drug prices set by pharmacy benefits managers (PBMs).
The global cancer vaccine market reached $US3483 million in 2010 and is set to grow at a compound annual growth rate of 12.7%,
A new report by CIHI* shows that healthcare spending in Canada is expected to grow by over $Can7 billion** this year, to reach $200.5 billion in 2011